Created by potrace 1.16, written by Peter Selinger 2001-2019beatandraise.com
Latest FinancialsFinancialsexperimental

Filings:

CategoryDateSearch FilingsInstitutional HoldersbetaEarnings TranscriptsbetaGlobal Search

SEC Edgar

Sanofi

SIC 2834 · Pharmaceutical Preparations
Support
aboutterms
$SNY

Sanofi

CIK:0001121404|SEC Filings
v3.25.4
Consolidated income statements - EUR (€)
€ in Millions, shares in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Profit (loss) [abstract]      
Net sales € 43,626 € 41,081 € 37,817 [1]
Other revenues 3,090 3,205 3,801 [1],[2]
Cost of sales (13,049) (13,205) (12,628) [1]
Gross profit 33,667 31,081 28,990 [1]
Research and development expenses (7,842) (7,394) (6,507) [1]
Selling and general expenses (9,543) (9,183) (8,933) [1]
Other operating income 1,231 1,089 979 [1]
Other operating expenses (5,655) (4,382) (3,443) [1]
Amortization of intangible assets (1,776) (1,749) (1,911) [1]
Impairment of intangible assets (2,241) (248) (896) [1]
Fair value remeasurement of contingent consideration (104) (96) (93) [1]
Restructuring costs and similar items (1,138) (1,396) (1,030) [1],[3]
Other gains and losses, and litigation (255) (470) (196) [1]
Operating income 6,344 7,252 6,960 [1],[4]
Financial expenses (563) (1,073) (1,293) [1],[4],[5]
Financial income 394 519 584 [1],[4],[5]
Income before tax and investments accounted for using the equity method 6,175 6,698 6,251 [1],[4],[6]
Income tax expense (1,043) (1,204) (1,017) [1],[6]
Share of profit/(loss) from investments accounted for using the equity method (155) 60 (136) [1]
Net income from continuing operations 4,977 5,554 5,098 [1]
Net income excluding the exchanged/held-for-exchange Animal Health business 2,874 64 338
Net income 7,851 5,618 5,436 [1]
Net income attributable to non-controlling interests 38 58 36 [1],[7]
Net income attributable to equity holders of Sanofi € 7,813 € 5,560 € 5,400 [1]
Average number of shares outstanding (in shares) 1,220.4 1,251.4 1,251.7 [1]
Average number of shares after dilution (in shares) 1,225.6 1,256.1 1,256.4 [1]
Basic earnings per share excluding the exchanged/held-for-exchange Animal Health business (in euros per share) € 4.05 € 4.40 € 4.06 [1]
Diluted earnings per share (in euros per share) 4.03 4.39 4.05 [1]
Basic earnings (loss) per share from discontinued operations 2.35 0.04 0.25 [1]
Basic earnings (loss) per share 6.40 4.44 4.31 [1]
Diluted earnings (loss) per share from discontinued operations 2.34 0.04 0.25 [1]
Diluted earnings (loss) per share € 6.37 € 4.43 € 4.30 [1]
[1] (a)2023 comparative figures were re-presented on a consistent basis from the date of the classification of Opella as a discontinued operation (2024).
[2] (a) 2023 comparative figures were re-presented on a consistent basis from the date of the classification of Opella as a discontinued operation (2024).
[3] (a) 2023 comparative figures were re-presented on a consistent basis from the date of the classification of Opella as a discontinued operation (2024).
[4] (a) 2023 comparative figures were re-presented on a consistent basis from the date of the classification of Opella as a discontinued operation (2024).
[5] (a) 2023 comparative figures were re-presented on a consistent basis from the date of the classification of Opella as a discontinued operation (2024).
[6] (a) 2023 comparative figures were re-presented on a consistent basis from the date of the classification of Opella as a discontinued operation (2024).
[7] (a) 2023 comparative figures were re-presented on a consistent basis from the date of the classification of Opella as a discontinued operation (2024).